Loading
IARC estimates 451 new cancer cases and 240 cancer deaths in Guam in 2024; the commonest new cancers are trachea, bronchus and lung, prostate and breast. This page is assembled automatically from OnCo's data: 9 trials with a site there, and says what OnCo does not yet hold.
Built partly from other countries' data. IARC's method code for Guam's incidence and mortality estimate is 5: rates based on incidence estimates or registry data from neighbouring countries. Read the figures as a regional estimate, not a count.
| Site | New cases | Rate | OnCo page |
|---|---|---|---|
| Trachea, bronchus and lung | 93 | 33.1 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Prostate | 57 | 43.5 | Prostate cancer |
| Breast | 55 | 49.5 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Colorectum | 47 | 19.0 | Colorectal cancer |
| Liver and intrahepatic bile ducts | 33 | 12.3 | Hepatocellular carcinoma |
| Non-Hodgkin lymphoma | 20 | 7.2 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Thyroid | 18 | 9.3 | Thyroid cancer |
| Stomach | 16 | 5.7 | Gastric & gastro-oesophageal junction cancer |
| Pancreas | 15 | 5.2 | Pancreatic ductal adenocarcinoma |
| Cervix uteri | 15 | 14.1 | Cervical cancer |
| Site | Deaths | Rate | OnCo page |
|---|---|---|---|
| Trachea, bronchus and lung | 81 | 28.5 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Liver and intrahepatic bile ducts | 26 | 9.4 | Hepatocellular carcinoma |
| Breast | 24 | 19.0 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Prostate | 21 | 14.0 | Prostate cancer |
| Colorectum | 16 | 6.0 | Colorectal cancer |
| Pancreas | 15 | 5.2 | Pancreatic ductal adenocarcinoma |
| Stomach | 14 | 5.0 | Gastric & gastro-oesophageal junction cancer |
| Non-Hodgkin lymphoma | 8 | 2.5 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Cervix uteri | 8 | 6.3 | Cervical cancer |
| Ovary | 6 | 4.6 | Ovarian cancer |
| Trial | Lead sponsor | ||||
|---|---|---|---|---|---|
| Phase 3 | Recruiting | National Cancer Institute (NCI) | 1,151 | 2026-10-07 | |
| Phase 3 | Recruiting | SWOG Cancer Research Network | 384 | 2026-03-31 | |
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) NCT02193282, NCT02194738, NCT02201992, NCT02595944 | Platform trial | Active not recruiting | National Cancer Institute (NCI) | 5,569 | 2026-10-01 |
NCI-MATCH (EAY131) NCT02465060 | Platform trial | Active not recruiting | National Cancer Institute (NCI) | 1,410 | 2026-10-01 |
| Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 830 | 2026-10-01 | |
| Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1,094 | 2026-10-01 | |
| Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 1,498 | 2026-09-02 | |
| Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1,007 | 2026-06-17 | |
| Phase 2/3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 793 | 2026-01-26 |
Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Guam, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Guam is open is on the registry page, under Contacts and Locations.
OnCo holds no institution, company or person in Guam.
OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Guam is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.
Guam is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.